by Plus Therapeutics | Jul 24, 2025 | Uncategorized
At Plus Therapeutics, our mission is to radically improve outcomes for patients with central nervous system (CNS) cancers through innovative, targeted radiotherapeutics. In a recent Xtalks Clinical Edge™ feature, our President and CEO, Dr. Marc Hedrick, sat down with...
by Plus Therapeutics | Jul 23, 2025 | LM
Plus Therapeutics is pleased to announce the receipt of a $1.6 million advance payment from the Cancer Prevention and Research Institute of Texas (CPRIT), the world’s second-largest public cancer research funding agency. This payment is part of the $17.6 million grant...
by Plus Therapeutics | Jul 22, 2025 | GBM
Each year on World Brain Day, the World Federation of Neurology (WFN) shines a global spotlight on the importance of brain health and the burden of neurological disorders. In 2025, this important observance carries the theme “Brain Health for All Ages”,...
by Plus Therapeutics | Jul 21, 2025 | Uncategorized
Central nervous system (CNS) cancers—including aggressive diseases like glioblastoma (GBM) and leptomeningeal metastases (LM)—remain among the most challenging cancers to treat. Despite decades of research, treatment options remain limited, and very few therapies have...
by Plus Therapeutics | Jul 16, 2025 | GBM
As we continue to honor GBM Awareness Day, Plus Therapeutics is proud to spotlight new insights from our RESPECT-GBM Phase 2 clinical trial—research aimed at addressing the urgent need for better treatment options for patients with recurrent glioblastoma (GBM). In a...
Recent Comments